Dexcom Faces FDA Warning Letter Over Manufacturing Issues, Shares Drop

Dexcom (NASDAQ: DXCM) received a warning letter from the U.S. Food and Drug Administration (FDA) after inspections at its key manufacturing sites in San Diego, California, and Mesa, Arizona. The letter cited concerns regarding manufacturing processes and quality management systems, leading to a nearly 7% drop in Dexcom’s stock price after hours.

While Dexcom did not disclose the number of violations observed, it stated that the warning is unlikely to impact its production capacity or fiscal 2025 sales outlook. The company has already responded to the FDA’s Form 483 and is preparing a formal written reply.

A Form 483 is issued by FDA inspectors when they identify manufacturing practices deemed objectionable. Companies receiving such notices must address the concerns to ensure compliance with regulatory standards.

Dexcom manufactures continuous glucose monitoring (CGM) systems at its San Diego headquarters and operates facilities in Mesa, Arizona, and Penang, Malaysia. According to recent filings, the company manages approximately 80,600 square feet of laboratory space and 159,600 square feet of controlled environment rooms across these locations.

Despite the FDA warning, Dexcom reassured investors that it remains committed to regulatory compliance and product quality. The company emphasized that it is working closely with the FDA to resolve the issues.

Dexcom’s stock decline reflects investor concerns over regulatory scrutiny, but the company maintains confidence in its ability to address the observations. Investors will closely watch for updates on the resolution process and potential impacts on future operations.

The FDA’s warning adds pressure on Dexcom as it competes in the growing CGM market, where regulatory compliance is crucial for maintaining trust and market share.